Suppr超能文献

免疫吸附治疗小儿肾移植后复发性局灶节段性肾小球硬化症:一项多中心法国队列研究。

Treatment by immunoadsorption for recurrent focal segmental glomerulosclerosis after paediatric kidney transplantation: a multicentre French cohort.

机构信息

CHU d'Angers, Pôle Femme-Mère-Enfant, Service de Pédiatrie, Angers, France.

Hôpital Robert Debré, Service de Néphrologie et Hémodialyse Pédiatrique, Paris, France.

出版信息

Nephrol Dial Transplant. 2018 Jun 1;33(6):954-963. doi: 10.1093/ndt/gfx214.

Abstract

BACKGROUND

Primary focal segmental glomerulosclerosis (FSGS) frequently recurs after kidney transplantation (KTx) in children. This can lead to delayed graft loss. As the management of children with recurrent FSGS is not well established, apheresis strategies could be a cornerstone to control the disease. Immunoadsorption (IA) is a recent apheresis therapy. There have been few studies examining IA in this setting. We report the results of IA for management of recurrent FSGS after KTx in children in France.

METHODS

We included all children treated with IA for early FSGS recurrence after KTx between January 2011 and June 2014 in France. We excluded genetic forms of FSGS. Patients' characteristics and technical data on IA were retrospectively collected. Recurrence was defined as nephrotic proteinuria during the post-transplantation period. Partial and complete remissions were defined when urine protein:creatinine ratios were less than 0.2 and 0.05 g/mmol, respectively.

RESULTS

Twelve patients, from six paediatric KTx units, presenting with FSGS recurrence between 0 and 21 days after KTx were treated with IA. Ten of 12 children were responders: 2 achieved partial remission and 8 complete remission. The decrease of proteinuria rapidly occurred within the first 10 sessions after initiating IA. After 3 months of IA, two patients maintained remission without IA and eight became IA dependent. No severe side effects were reported.

CONCLUSIONS

Our study reports on the efficacy of IA in the recurrence of FSGS after KTx in children. Further prospective controlled studies are required to confirm these results and to optimize the management of FSGS recurrence after paediatric KTx.

摘要

背景

原发性局灶节段性肾小球硬化症(FSGS)在儿童肾移植(KTx)后经常复发,导致移植物延迟丢失。由于儿童复发性 FSGS 的治疗方法尚未确定,因此清除疗法策略可能是控制疾病的基石。免疫吸附(IA)是最近的一种清除疗法。在这种情况下,对 IA 的研究很少。我们报告了法国儿童 KTx 后复发性 FSGS 采用 IA 治疗的结果。

方法

我们纳入了 2011 年 1 月至 2014 年 6 月期间在法国因 KTx 后早期 FSGS 复发而接受 IA 治疗的所有儿童。我们排除了 FSGS 的遗传形式。回顾性收集患者特征和 IA 的技术数据。复发定义为移植后期间肾病性蛋白尿。当尿蛋白/肌酐比值分别小于 0.2 和 0.05 g/mmol 时,分别定义为部分缓解和完全缓解。

结果

12 例患儿,来自 6 个儿科 KTx 单位,在 KTx 后 0 至 21 天出现 FSGS 复发,接受 IA 治疗。12 例患儿中的 10 例为应答者:2 例获得部分缓解,8 例完全缓解。开始 IA 后 10 次内蛋白尿迅速减少。IA 后 3 个月,2 例患儿在没有 IA 的情况下保持缓解,8 例患儿依赖 IA。未报告严重副作用。

结论

我们的研究报告了 IA 在儿童 KTx 后 FSGS 复发中的疗效。需要进一步前瞻性对照研究来证实这些结果,并优化儿科 KTx 后 FSGS 复发的管理。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验